Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
This study will evaluate the long-term safety, efficacy, and pharmacodynamics of elexacaftor
 (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in
 subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating
 or residual function mutation (F/G and F/RF genotypes).
Key Inclusion Criteria:

 -  Completed study drug treatment in parent study (VX18-445-104); or had study drug
 interruption(s) in parent study but completed study visits up to the last scheduled
 visit of the Treatment Period in the parent study

 Key Exclusion Criteria:

 -  History of study drug intolerance in parent study

 Other protocol defined Inclusion/Exclusion criteria may apply